Associated Press

Orlando, Florida

The first head-to-head comparison of popular statin drugs suggests that lowering cholesterol more aggressively than the current US guidelines recommend can completely stop dangerous clogging of the arteries. The results address one of the biggest questions in cardiology: How low should bad cholesterol go? For now, the answer seems to be: As low as possible.

Nevertheless, other experts caution that it is too soon to rewrite guidelines, although that may be in the offing as several new studies tackle this issue in the next few years.

The latest study compared two popular statin pills, Lipitor and Pravachol. It found that Lipitor did a considerably better job of both lowering cholesterol and controlling the insidious build-up of gunk inside the arteries when given to people with serious heart disease.

Exactly why, though, is unclear. The benefit could not be totally explained by the lower cholesterol levels. Researchers wondered if some other property of Lipitor, such as it stronger effect on inflammation, accounted for its more potent effects.

The study was sponsored by Liptor’s maker, Pfizer. Another similar but larger study is nearing completion, sponsored Bristol-Myers Squibb, which makes Pravachol.

Doctors have long debated how low people with heart trouble should drive down their cholesterol. Guidelines recommend getting LDL, the bad cholesterol, down to 100. But many have wondered whether lower is better.

The latest study lowered that target to 80 and found the more rigorous treatment seemed to stop artery clogging in its tracks.

“There is no such thing as too low an LDL. That’s what the data seem to show,” said Dr Steven Nissen of the Cleveland Clinic. He presented the results at a meeting of the American Heart Association in Orlando.

The study involved 654 adults with LDL over 125 who had symptoms of coronary disease. They were randomly assigned to get either 40 milligrams of Pravachol or 80 milligrams of Lipitor, the top doses available of the two drugs. At the time the study began in 1999, Lipitor was considered to be the most powerful statin in the market.

The doctors used highly sensitive intravascular ultrasound to watch what happened to the buildup, known as plaque, in volunteers’ heart arteries. After 18 months of typical follow-up, average LDL was 110 in the Pravachol patients and 79 in those on Lipitor.

The volume of plaque in their arteries increased almost three per cent in the Pravachol patients, while it actually regressed a fraction of one per cent in those on Lipitor. However, the shrinkage was too small to be statistically meaningful.

Even when people on Pravachol reached the same LDL levels as those on Lipitor, their plaque build-up was worse. Nissen speculated that Lipitor’s especially powerful effect on inflammation of the blood vessels could be the reason.

In this study, Lipitor lowered this inflammation, as measured by a substance called C-reactive protein, by 36 per cent, while Pravachol reduced it by five per cent.

“I think Pravachol is a good drug,” Nissen said. “I just think it’s not the best drug. I do respect that all statins work. But there are differences across the class.”

Julie Keenan, a spokeswoman for Bristol-Myers Squibb, noted that the study did not measure actual heart complications, such as heart attacks and death, and earlier studies have shown that Pravachol reduces the risk of these disasters.

Dr Christopher Cannon of Boston’s Brigham and Women’s Hospital is directing Bristol-Myers Squibb’s comparison of the two drugs and said that study will judge which one does a better job of keeping people alive and healthy. He said Nissen’s finding that Lipitor is more effective at blocking plaque is “fascinating,” but he asked, “Is it important?”

Meanwhile, Dr Raymond Gibbons of the Mayo Clinic said cardiologists will demand hard evidence that more aggressive cholesterol lowering saves lives before they make wholesale switches in therapy.

“We are not treating the people who need it, period, to even moderate LDL levels,” Gibbons said. “We are not getting them to even 110. This study suggests we need to go to a new level.”

Guidelines from the US National Institute of Health’s National Cholesterol Education Program, last revised two years ago, set LDL under 100 as the target for treatment in people with heart disease.